Cat. No. 2839
Alternative Names: Keppra, UCB L059
Chemical Name: (2S)-(2-Oxopyrrolidin-1-yl)butyrami
Biological ActivityAntiepileptic that displays distinctive properties from conventional antiepileptic drugs. Displays potent seizure protection in animal models of chronic epilepsy but lacks activity in acute seizure models. Binds synaptic vesicle protein 2A (SV2A) and inhibits Na+-dependent Cl-/HCO3- exchange.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Lynch et al (2004) The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proct.Natl.Acad.Sci. USA 101 9861.
Smedt et al (2007) Levetiracetam: the profile of a novel anticonvulsant drug - part I: preclinical data. CNS Drug Rev. 13 43. PMID: 17461889.
Ueda et al (2007) Effect of levetiracetam on molecular regulation of hippocampal glutamate and GABA transporters in rats with chronic seizures induced by amygdalar FeCl3 injection. Brain Res. 1151 55. PMID: 17408599.
If you know of a relevant citation for this product please let us know.
Keywords: Levetiracetam, supplier, Anti-epileptic, binds, SV2A, Exocytosis, Endocytosis, Protein, Translocation, UCBL059
Find multiple products by catalog number
New Products in this Area
PAD4 inhibitorGNF 7
Ras signaling inhibitor; inhibits Ack1 and GCKPMX 53
Potent C5a receptor antagonist
One Day Symposium
January 12, 2016